The Sentinel

THE OFFICIAL BLOG OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC).

Wednesday, January 19, 2022

Letter From the Editor - January


Hello JITC Readers,

pedro-romero_1__1_.jpg
Welcome to the New Year and one that happens to be of great significance to the journal, as JITC will celebrate its 10th anniversary in 2022. It is humbling to look back on how far JITC has come in the past 10 years, and we are all excited for what the future holds.
Of course, it is the top-caliber articles published in JITC that have supported the journal’s ascent to being among the most highly-ranked oncology and immunology journals. This past year was no exception, and we are highlighting some of the top-most accessed and downloaded articles from 2021 in this month’s special feature.
The original research spotlighted in this month’s digest offers new insights on a diverse array of emerging areas in the immunotherapy field.
Jinzhu Mao and colleagues offer a detailed metagenomic census of the gut microbiome in patients with hepatobiliary cancers being treated with immunotherapy, showing that the presence of many lower-level taxa is not “one-size-fits-all” for clinical benefit.
A novel feedback loop involving CCL18-mediated crosstalk between tumor-associated macrophages and ovarian carcinoma cells promoting epithelial-to-mesenchymal transition and other invasive characteristics is described by Lingli Long et al.
Sub-cytotoxic doses of a metabolite of the topoisomerase I inhibitor irinotecan were demonstrated to enhance responses to anti-PD-1 via activation of FOXO3 and enhanced tumor infiltration of natural killer cells by Young Min Chung and colleagues.
Finally, Giuseppe Minniti et al present the results of a retrospective study indicating that the addition of immunotherapy to postoperative stereotactic radiosurgery reduces the risk of leptomeningeal disease for patients with melanoma and non-small cell lung cancer brain metastases.
Looking forward to what is in store for 2022!
 
Best,

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer

No comments:

Post a Comment